Mode
Text Size
Log in / Sign up
N/A Completed N=330

Post Marketing Surveillance Study of Champix in Smoking Cessation for Filipino Patients

Source: ClinicalTrials.gov NCT00794365 ↗
Enrolled (actual)
330
Serious AEs
0.0%
Results posted
Dec 2010
Primary outcomePrimary: Percentage of Participants With 7-day Point Prevalence of Smoking Cessation at Week 4 — 58.79 percentage of participants

Summary

The primary objective of this Post-Marketing Study is to monitor the safety of a novel smoking cessation drug Varenicline (Champix™) 0.5 mg and 1 mg tablets as used in clinical practice for 12 weeks among Filipino smokers. The secondary objective is to further evaluate the effectiveness of Varenicline (Champix™) as an aid in smoking cessation based on the 7-day point prevalence of smoking cessation

Outcome Measures

OutcomeResultp-value
PRIMARY
Percentage of Participants With 7-day Point Prevalence of Smoking Cessation at Week 4
58.79 —
PRIMARY
Percentage of Participants With 7-day Point Prevalence of Smoking Cessation at Week 8
61.52 —
PRIMARY
Percentage of Participants With 7-day Point Prevalence of Smoking Cessation at Week 12
57.58 —

Eligibility Criteria

Inclusion Criteria

  • Smoking adults aged ≥ 18 years intending to quit tobacco use who are prescribed Varenicline (Champix™) by their Physicians and those who are prescribed with Varenicline (Champix™) for the first time.

Exclusion Criteria

  • Subjects in whom varenicline (Champix™) may be taken in a manner that is not according to the approved local product document.
  • Pregnant or lactating women, or women of childbearing potential not using an acceptable method of contraception
  • Subjects with known hypersensitivity to varenicline.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00794365). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search